This decision comes in the wake of an injunction received by Washington state’s Medicaid program last Friday to provide hepatitis C drugs for all patients, regardless of sickness level. The ruling responded to a class-action lawsuit filed on behalf of two Washington Medicaid recipients who were denied the costly drug.
Prior to the Florida amendment, patients could only receive the hepatitis C drug if they were at a fibrosis level of three or four, meaning they had extensive liver damage. Under the new criteria, fibrosis level is no longer a requirement.
Patients typically require two to six months of treatment with the drug, which can cost up to $180,000. Depending on patient history and the type of drug being used, medications are 96 to 100 percent effective.
More articles on supply chain:
Judge orders Washington Medicaid to cover lifesaving hepatitis C drugs for all
Massachusetts lawmakers to vote on bill for transparency into prescription drug costs
Viewpoint: High drug prices may not be high enough
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
